Gemcitabine is a purine analog with known activity in many solid tumors, namely lung, breast, pancreatic, genitourinary and head/neck cancers. Cardiac toxicity is a rare event and only one report previously described atrial fibrillation (AF) as a consequence of gemcitabine infusion. We report two cases of women suffering from lung cancer who were treated with gemcitabine. Both patients were admitted to hospital for paroxysmal AF occurring 12-24 h after the infusion of the drug. In the first case a sinus rhythm was spontaneously repristinated when AF occurred for the first time, while the second episode required an anti-arrhythmic drug to interrupt the dysrhythmia. In the second case, the patient had to be treated with digitalis glycoside to control the ventricular response without attaining a sinus rhythm. We could not recognize any other precipitating factor beyond the infusion of gemcitabine as a cause for the arrhythmia. Both cases were treated with gemcitabine for lung cancer and we observed the appearance of AF less than 24 h after drug administration. We assume that 2',2'-difluorodeoxyuridine, an active metabolite of gemcitabine, could be responsible for the toxic effect. We conclude that AF is an unusual, but potentially dangerous, side-effect of gemcitabine infusion. The arrhythmia should be suspected whenever patients complain of dyspnea and palpitations beginning 12-24 h after treatment. In these cases, the treatment of AF consists of anti-arrhythmic drugs in order to repristinate a sinus rhythm or control the heart rate

Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity / D. Ferrari, C. Carbone, C. Codecà, L. Fumagalli, L. Gilardi, D. Marussi, T. Tartaro, S. Oldani, F. Zannier, P. Foa. - In: ANTI-CANCER DRUGS. - ISSN 0959-4973. - 17:3(2006 Mar), pp. 359-361. [10.1097/00001813-200603000-00016]

Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity

D. Ferrari;C. Carbone;D. Marussi;T. Tartaro;F. Zannier;P. Foa
2006

Abstract

Gemcitabine is a purine analog with known activity in many solid tumors, namely lung, breast, pancreatic, genitourinary and head/neck cancers. Cardiac toxicity is a rare event and only one report previously described atrial fibrillation (AF) as a consequence of gemcitabine infusion. We report two cases of women suffering from lung cancer who were treated with gemcitabine. Both patients were admitted to hospital for paroxysmal AF occurring 12-24 h after the infusion of the drug. In the first case a sinus rhythm was spontaneously repristinated when AF occurred for the first time, while the second episode required an anti-arrhythmic drug to interrupt the dysrhythmia. In the second case, the patient had to be treated with digitalis glycoside to control the ventricular response without attaining a sinus rhythm. We could not recognize any other precipitating factor beyond the infusion of gemcitabine as a cause for the arrhythmia. Both cases were treated with gemcitabine for lung cancer and we observed the appearance of AF less than 24 h after drug administration. We assume that 2',2'-difluorodeoxyuridine, an active metabolite of gemcitabine, could be responsible for the toxic effect. We conclude that AF is an unusual, but potentially dangerous, side-effect of gemcitabine infusion. The arrhythmia should be suspected whenever patients complain of dyspnea and palpitations beginning 12-24 h after treatment. In these cases, the treatment of AF consists of anti-arrhythmic drugs in order to repristinate a sinus rhythm or control the heart rate
Atrial fibrilation; Cardiac toxicity; Gemcitabine
Settore MED/06 - Oncologia Medica
mar-2006
http://ovidsp.tx.ovid.com/spb/ovidweb.cgi?WebLinkFrameset=1&S=MIEAFPBKLJDDEDDANCGLGBPJFKOCAA00&returnUrl=http%3a%2f%2fovidsp.tx.ovid.com%2fspb%2fovidweb.cgi%3f%26Full%2bText%3dL%257cS.sh.15.16%257c0%257c00001813-200603000-00016%26S%3dMIEAFPBKLJDDEDDANCGLGBPJFKOCAA00&directlink=http%3a%2f%2fgraphics.tx.ovid.com%2fovftpdfs%2fFPDDNCPJGBDALJ00%2ffs047%2fovft%2flive%2fgv024%2f00001813%2f00001813-200603000-00016.pdf&filename=Gemcitabine+and+atrial+fibrillation%3a+a+rare+manifestation+of+chemotherapy+toxicity.
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/52140
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 33
  • ???jsp.display-item.citation.isi??? 25
social impact